What’s on your mind on this Monday morning and are you caffeinated enough yet? Depending on where you live it may even be time for dinner, bed, or already early Tuesday. Here are some Monday musings… To get safe and effective stem cell treatments to patients in a responsible, compliant manner you need commercial efforts […]
Monday morning musings: stocks, ISSCR, grants, CRISPR, New Book Read More »
Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy
Bioheart on the edge in 2015? Read More »
Here is a link to the Ocata website, marking the start of a new era for what was formerly Advanced Cell Technology or ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently
ACT reinventing itself with new name Ocata Therapeutics Read More »
Who might make a fantastic new CIRM President? The California stem cell community is abuzz with this question. This new President will not only lead CIRM today, but also in all likelihood will steer CIRM in its new incarnation after 2017, what I’ve called CIRM 2.0. At least that would be ideal. CIRM has posted a
Dozen Candidates To Be New CIRM President Read More »
It wasn’t so long ago that I did a post explaining why after following the company for years, I finally bought a small amount of stock in the stem cell biotech, Advanced Cell Technology (ACT; symbol ACTC). In part it was motivated by my enthusiasm to see them publishing a paper, a very preliminary paper,
Why Lanza and I sold ACT stock Read More »
I’ve written before about concerns related to longevity research hype from Harvard professor David Sinclair. The media often eats up statements about longevity from Sinclair and a few other scientists in that space. There is also endless coverage of the latest exploits of wealthy health influencer Bryan Johnson. For that reason it was refreshing to
Refreshing WSJ piece on longevity ‘guru’ David Sinclair Read More »
What do you think of when I mention Stanford professor Mike Snyder and self-help guru Tony Robbins together? I would not necessarily have imagined them forming a connection but science is full of surprises. I’ve admired Snyder’s work in genetics for a long time. I’m most familiar these days with Robbins for his interest in
Gene editing continues to advance both in the clinic trial arena and at more basic science levels including a report on a new approach called click editing. The two gene editing papers below highlight the variety of tools now available. Gene Editing papers including click editing Click editing enables programmable genome writing using DNA polymerases
Recommended reads: click editing, CRISPR v. progeria, diapause transcriptional program Read More »
Would you guess that Elon Musk might be into using biotechnology in a high-profile way to try to live far longer than usual, say to age 150? That would have been my assumption. There are countless things about Elon Musk that I really don’t like. I also don’t see many issues on which we are
Something Elon Musk & I agree on: pushing back on anti-aging bluster Read More »
Readers of The Niche have asked me many questions about stem cells for autoimmune disease but the puzzle of why women get these conditions more often than men hasn’t come up before here. For instance, why is MS so much more common in women than men? It’s remained somewhat of a mystery over the years.